Centessa Pharmaceuticals Plans Major Public Offering of ADSs
Centessa Pharmaceuticals Plans Major Public Offering
BOSTON and LONDON — Centessa Pharmaceuticals plc (NASDAQ: CNTA), a clinical-stage pharmaceutical innovator with a mission to develop transformative therapies, has announced an exciting new opportunity. The company is initiating a public offering valued at $150 million of American Depositary Shares (ADSs), with each share representing one ordinary share.
Details of the Offering
All ADSs in this offering will be provided directly by Centessa, and the company plans to grant underwriters a 30-day option to acquire an additional $22.5 million of ADSs. This offering is contingent on market conditions and other relevant factors, meaning that the final size and terms may vary significantly.
Management of the Offering
A group of reputable financial entities has taken on the role of joint book-running managers for this offering. The team includes Goldman Sachs & Co. LLC, Leerink Partners, Evercore ISI, Guggenheim Securities, and BMO Capital Markets. Their expertise will play a crucial role in navigating this public offering successfully.
Regulatory Framework
The ADSs are being offered in accordance with a registration statement on Form S-3 that has been submitted to the U.S. Securities and Exchange Commission (SEC). It automatically came into effect upon submission, streamlining the process for both the company and interested investors. A preliminary prospectus supplement, along with an accompanying prospectus, will soon be filed with the SEC. Investors can expect detailed information about this offering to be available on the SEC's website.
About Centessa Pharmaceuticals
Centessa Pharmaceuticals is dedicated to developing medicines that can significantly alter patient outcomes. The company’s research initiatives are particularly noteworthy, as they include cutting-edge programs targeting hemophilia, innovative orexin agonist treatments for narcolepsy and sleep disorders, and an impressive immuno-oncology initiative centered around their pioneering LockBody® technology platform. Centessa operates under the belief that each of its drug development programs holds the promise of establishing new standards of care within the healthcare landscape.
Company Contact Information
For inquiries or further information regarding this public offering, Kristen K. Sheppard, the Senior Vice President of Investor Relations, is available to assist. Interested parties can contact her directly at investors@centessa.com.
Frequently Asked Questions
What is the purpose of Centessa's new public offering?
The offering aims to raise funds for further development of innovative therapies and support ongoing research programs.
How much is Centessa looking to raise from this offering?
Centessa Pharmaceuticals is seeking to raise $150 million, with an option for underwriters to purchase an additional $22.5 million.
Who is managing the offering?
Goldman Sachs & Co. LLC, Leerink Partners, Evercore ISI, Guggenheim Securities, and BMO Capital Markets are acting as joint book-running managers for the offering.
What are the primary programs Centessa is focusing on?
Centessa's key programs include treatments for hemophilia, narcolepsy, and advanced immuno-oncology solutions based on LockBody® technology.
How can investors learn more about this offering?
Investors can find more information through the preliminary prospectus supplement that will be filed with the SEC and through direct company communications.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.